ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,745.37
      0.40%
      US Tech 100
      19,553.60
      -0.13%
      Dow Jones
      42,175.11
      0.62%
      Brent Oil
      71.225
      0.39%
      Bitcoin
      65,400.00
      0.33%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Vertex Pharmaceuticals Inc (VRTX)

      7. Vertex Pharmaceuticals Inc (VRTX) News

      VRTX

      Vertex Pharmaceuticals (VRTX)

      Vertex Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:VRTX
      DateTimeSourceHeadlineSymbolCompany
      09/26/20249:00AMPR Newswire (Canada)Vertex annonce l'acceptation par Santé Canada de la soumission de drogue nouvelle pour l'association vanzacaftor/tézacaftor/deutivacaftor, un traitement d'association triple de nouvelle génération pour la fibrose kystiqueNASDAQ:VRTXVertex Pharmaceuticals Inc
      09/26/20249:00AMPR Newswire (Canada)Vertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic FibrosisNASDAQ:VRTXVertex Pharmaceuticals Inc
      09/26/20247:07AMBusiness WireVertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis ConferenceNASDAQ:VRTXVertex Pharmaceuticals Inc
      09/25/20243:51PMPR Newswire (Canada)Santé Canada accorde l'autorisation de mise sur le marché de la première thérapie d'édition génomique CRISPR/Cas9, CASGEVY® (exagamglogène autotemcel), pour le traitement de l'anémie falciforme et de la bêta-thalassémie dépendante des transfusiNASDAQ:VRTXVertex Pharmaceuticals Inc
      09/25/20243:50PMPR Newswire (Canada)Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaNASDAQ:VRTXVertex Pharmaceuticals Inc
      09/04/20244:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      09/04/20244:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/30/20244:47PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/30/20244:23PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/22/20248:00AMBusiness WireVertex to Participate in Upcoming September Investor ConferencesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/16/20244:04PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/12/20244:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/08/20244:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/08/202411:47AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/07/20247:12PMBusiness WireVertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in EnglandNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/07/20249:52AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/02/20244:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/02/20244:03PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRTXVertex Pharmaceuticals Inc
      08/01/20244:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/01/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/01/20244:01PMBusiness WireVertex Reports Second Quarter 2024 Financial ResultsNASDAQ:VRTXVertex Pharmaceuticals Inc
      08/01/20243:34PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/30/20243:25PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/30/20241:10PMBusiness WireVertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute PainNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/25/20244:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/24/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/24/202412:27PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/22/20241:16PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/17/20244:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
      07/15/20249:00AMPR Newswire (Canada)Santé Canada autorise la commercialisation de TRIKAFTA(MD) (éléxacaftor/tézacaftor/ivacaftor et ivacaftor) chez les personnes atteintes de fibrose kystique âgées de 2 ans et plus présentant certaines mutations raresNASDAQ:VRTXVertex Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:VRTX

      Your Recent History

      LSE
      79TF
      Paragon M. 47
      LSE
      NKE2
      Nats En R 31
      Delayed Upgrade Clock